


# FINANCIAL TEAR SHEET

### Corporate Profile

AveXis, Inc. is a clinical-stage gene therapy company, dedicated to developing and commercializing novel treatments for patients suffering from rare and life-threatening neurological genetic diseases. Our initial product candidate, AVXS-101, is our proprietary gene therapy product candidate currently in development for the treatment of spinal muscular atrophy, or SMA, Type 1, the leading genetic cause of infant mortality. The U.S. Food and Drug Administration, or FDA, has granted AVXS-101 Orphan Drug Designation for the treatment of all types of SMA and Breakthrough Therapy Designation, as well as Fast Track Designation for the treatment of SMA Type 1. In addition to developing AVXS-101 to treat SMA Type 1, we plan to develop AVXS-101 to treat additional SMA types and develop other novel treatments for rare neurological genetic diseases.

#### Stock Information

AVXS (Common Stock)	
Exchange	NASDAQ GS (US Dollar)
Price	\$83.65
Change (%)	<b>4</b> 0.56 (0.67%)
Volume	464,977
52 Week High	\$85.98
52 Week Low	\$31.55
Market Cap	\$2,309,449,824
Rolling EPS	-3.54
PE Ratio	0
Shares Outstanding	27,794,558
Data as of 07/21/17 4:00 p.m. ET	



#### **Recent Headlines**

06/26/17

AveXis Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares

06/20/17

**AveXis Announces Pricing of Public Offering of Common Stock** 

06/19/17

**AveXis Announces Proposed Public Offering of Common Stock** 

### **Upcoming Events**

There are currently no events scheduled.

## **SEC Filings**

Filing Date	Form
07/14/17	8-K
07/05/17	4
06/22/17	8-K
06/22/17	424B5

# **Primary IR Contact**

Vice President, Investor Relations and Corporate Communications

Jim Goff

Phone: (650) 862-4134 E-mail: jgoff@avexis.com

Data provided by Nasdaq. Minimum 15 minutes delayed.